论文部分内容阅读
目的探讨低分子肝素(LMWH)在冠心病患者介入治疗(PCI)中应用的临床疗效。方法 98例冠心病患者,随机分为观察组(采用低分子肝素治疗)和对照组(采用普通肝素治疗),各49例。比较两组患者术后不良反应发生率、术后股动脉穿刺局部平均压迫止血时间、局部血肿发生率。结果观察组不良反应发生率为4.08%,明显低于对照组的20.41%,差异具有统计学意义(P<0.05)。与对照组对比,观察组术后股动脉穿刺局部平均压迫止血时间明显更短,局部血肿发生率明显更低,差异具有统计学意义(P<0.05)。结论采用低分子肝素应用于冠心病介入治疗具有明显的疗效与安全性,值得临床广泛应用以及推广。
Objective To investigate the clinical effect of low molecular weight heparin (LMWH) in the interventional therapy of coronary heart disease (PCI). Methods A total of 98 patients with coronary heart disease were randomly divided into observation group (treated with low molecular weight heparin) and control group (treated with unfractionated heparin), 49 cases each. The incidence of postoperative adverse reactions, the mean time of hemostasis after local femoral artery puncture and the incidence of local hematoma were compared between the two groups. Results The incidence of adverse reactions in the observation group was 4.08%, which was significantly lower than that in the control group (20.41%), the difference was statistically significant (P <0.05). Compared with the control group, the observation group had significantly shorter hemostasis time after local femoral artery puncture, and the incidence of local hematoma was significantly lower (P <0.05). Conclusion The application of low molecular weight heparin in the interventional therapy of coronary heart disease has obvious curative effect and safety, which is worth widely used in clinic and popularized.